Fig. 4

Safety dose assessment in terms of 5 indicators of hematology. A–E WBC (A), RBC (B), HGB (C), HCT (D) and MCHC (E) were assessed at 7 days after starting the combination formulation treatment. F–J WBC (F), RBC (G), HGB (H), HCT (I) and MCHC (J) were assessed at 14 days after starting the combination formulation treatment. See Table 3 for description of groups. HCT, Hematocrit; HGB, hemoglobin; MCHC, mean corpuscular hemoglobin concentration; ns, not significant; RBC, red blood cells; WBC, white blood cells